Pages that link to "Q44267005"
Jump to navigation
Jump to search
The following pages link to Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. (Q44267005):
Displaying 50 items.
- Correction of mucopolysaccharidosis type IIIb fibroblasts by lentiviral vector-mediated gene transfer (Q24534147) (← links)
- Gene therapy for mucopolysaccharidosis (Q24631135) (← links)
- Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics (Q28141424) (← links)
- Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells (Q30501325) (← links)
- Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium (Q30957737) (← links)
- Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier (Q34026516) (← links)
- Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors (Q34028579) (← links)
- Gene therapy in lysosomal diseases (Q34114285) (← links)
- From gene transfer to gene therapy in lysosomal storage diseases affecting the central nervous system (Q34224260) (← links)
- Regulatable and cell-type specific transgene expression in glial cells: prospects for gene therapy for neurological disorders (Q34361466) (← links)
- Genetic engineering within the adult brain: implications for molecular approaches to behavioral neuroscience (Q34375860) (← links)
- Gene therapy for lysosomal storage disorders: a good start (Q34502978) (← links)
- Combination therapies for lysosomal storage disease: is the whole greater than the sum of its parts? (Q34982831) (← links)
- Gene therapy for the central nervous system in the lysosomal storage disorders (Q34997896) (← links)
- Lysosomal storage disorders: diagnostic dilemmas and prospects for therapy (Q35037640) (← links)
- Therapeutic Gene Transfer to the Nervous System Using Viral Vectors (Q35112002) (← links)
- Progress and problems with the use of viral vectors for gene therapy (Q35120176) (← links)
- Gene therapy for mucopolysaccharidosis. (Q35216675) (← links)
- Gene therapy for neurologic manifestations of mucopolysaccharidoses (Q35362251) (← links)
- Glycosaminoglycan storage disorders: a review (Q35367599) (← links)
- Gene Transfer Strategies for Correction of Lysosomal Storage Disorders (Q35570276) (← links)
- The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier (Q35585191) (← links)
- Clinical applications involving CNS gene transfer (Q35899850) (← links)
- CNS-directed gene therapy for lysosomal storage diseases (Q35923467) (← links)
- Rational targeting for prion therapeutics. (Q35990277) (← links)
- Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain (Q36147515) (← links)
- Lentiviral vectors for use in the central nervous system. (Q36364923) (← links)
- Genetic medicines: treatment strategies for hereditary disorders (Q36423907) (← links)
- Gene therapy for lysosomal storage diseases. (Q36424472) (← links)
- Neonatal cellular and gene therapies for mucopolysaccharidoses: the earlier the better? (Q36582259) (← links)
- Transduction of brain by herpes simplex virus vectors (Q36681937) (← links)
- Novel candidate disease for gene therapy: metachromatic leukodystrophy (Q36909371) (← links)
- Large animal models of neurological disorders for gene therapy (Q37265519) (← links)
- Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors (Q37695619) (← links)
- Genetic therapy for the nervous system (Q37856565) (← links)
- Emerging therapies for neurodegenerative lysosomal storage disorders - from concept to reality. (Q37876354) (← links)
- Central nervous system delivery of helper-dependent canine adenovirus corrects neuropathology and behavior in mucopolysaccharidosis type VII mice. (Q38287249) (← links)
- Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector (Q39611260) (← links)
- Improvement of skeletal lesions in mice with mucopolysaccharidosis type vii by neonatal adenoviral gene transfer (Q40619728) (← links)
- Plasmid-based gene transfer ameliorates visceral storage in a mouse model of Sandhoff disease (Q40656536) (← links)
- Lentiviral vectors for gene delivery to normal and demyelinated white matter (Q40669514) (← links)
- Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors (Q40746258) (← links)
- Analysis of gene transfer efficiency of retrovirus producer cell transplantation for in situ gene transfer to hematopoietic cells (Q40829011) (← links)
- Treatment of the mouse model of mucopolysaccharidosis type IIIB with lentiviral-NAGLU vector (Q42229261) (← links)
- Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders (Q42428990) (← links)
- Efficient CNS gene delivery by intravenous injection (Q42856452) (← links)
- In vitro gene therapy of mucopolysaccharidosis type I by lentiviral vectors (Q44016335) (← links)
- Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. (Q44103069) (← links)
- Long-term normalization in the central nervous system, ocular manifestations, and skeletal deformities by a single systemic adenovirus injection into neonatal mice with mucopolysaccharidosis VII. (Q44325000) (← links)
- Widespread distribution of beta-hexosaminidase activity in the brain of a Sandhoff mouse model after coinjection of adenoviral vector and mannitol. (Q44576921) (← links)